Illumina, Inc. · NASDAQ:ILMN
Illumina — Investor Presentation (May 2018)
19 slides from Illumina's investor presentation, May 3, 2018
Slide 1: Illumina Investor Presentation
Illumina Investor Presentation May 3, 2018 © 2017 Illumina, Inc. All rights reserved.
Slide 2: Safe Harbor Statement
Safe Harbor Statement This communication may contain forward-looking statements that involve risks and uncertainties, including our financial outlook and guidance for fiscal 2018 and expectations regarding the development and commercialization of new products. Among the important factors that could
Slide 3: Our Mission
Our Mission To improve human health by unlocking the power of the genome 3
Slide 4: Our Technology
Our Technology Integrated workflows from sample-to-answer SEAMLESS WORKFLOW SOLUTIONS ENABLE MARKETS Flexible, Simplified Custom Integrated economical library prep content analysis sequencing 4
Slide 5: Sequencing Power for Every Scale
Sequencing Power for Every Scale The broadest portfolio offering available Sequencing ™ ™ ® ® ® ® ® iSeq MiniSeq MiSeq NextSeq HiSeq HiSeq X NovaSeq System 4000 Five/Ten 6000 Output per run 1.2 Gb 7.5 Gb 15 Gb 120 Gb 1.5 Tb 1.8 Tb 1 Tb - 6 Tb 1 Instrument $19.9K $49.5K $99K $275K $900K $6M2/$10M2 $9
Slide 6: Product & Customer Diversity
Product & Customer Diversity Robust recurring revenue with balanced customer base1 Revenue by Product/Service Revenue By Geography Asia Pacific Consumables Greater 8% 64% China 11% Europe Americas 23% 58% Instrument 19% Service / other 17% 6 1. Based on fiscal year 2017
Slide 7: First Quarter Results
First Quarter Results1 Revenue and Non-GAAP EPS exceeded expectations Revenue Non-GAAP EPS2 Non-GAAP Non-GAAP ($ in millions) gross margin operating margin $1.45 $782 29.5% 69.8% $598 $0.64 66.4% 17.5% 31% 127% 340 Increase 1200 Increase bps bps Q1’17 Q1’18 Q1’17 Q1’18 Q1’17 Q1’18 Q1’17 Q1’18 7 1. F
Slide 8: Balance Sheet / Cash Flow
Balance Sheet1 / Cash Flow2 Strong cash position Cash Flow from Free Cash Flow Cash and Short- Operations ($ in millions) term Investments ($ in millions) ($ in millions) $255 $165 $2,373 $168 $1,778 $85 52% 94% 33% Increase Increase Increase As of As of Q1’17 Q1’18 Q1’17 Q1’18 4/2/17 4/1/18 8 1. Ba
Slide 9: Historic Revenue and Non-GAAP EPS
Historic Revenue and Non-GAAP EPS Innovation drives profitable growth Revenue CAGR: 19% EPS CAGR1: 20% Non-GAAP EPS1 Revenue ($millions) $3,000 $4.00 $3.50 $2,500 $3.00 $2,000 $2.50 $1,500 $2.00 $1.50 $1,000 $1.00 $500 $0.50 $0 $0.00 2012 2013 2014 2015 2016 2017 9 1. Non-GAAP EPS attributable to Il
Slide 10: 2018 Guidance
2018 Guidance Double-digit revenue growth in 2018 20181 Revenue1 15% - 16% GAAP EPS2 $4.45 - $4.55 Non-GAAP EPS2 $4.75 - $4.85 10 1. Guidance given via 8-k and press release on April 24, 2018; assumes constant currency rates from April 24, 2018 2. Attributable to Illumina stockholders
Slide 11: Who We Serve
Who We Serve Innovation drives expanding market opportunities Reproductive Health Oncology Population Sequencing Research Complex Disease Consumer Infectious Disease Forensics Agriculture Genetic Health BioPharm 11
Slide 12: Appendix
Appendix Non-GAAP Reconciliations 12
Slide 13: Itemized Reconciliation Between GAAP and Non-GAAP Earnings Per Share
Itemized Reconciliation Between GAAP and Non-GAAP Earnings Per Share Attributable to Illumina Stockholders: Years Ended Dollars in millions, except per share amounts December 31, January 1, January 3, December 28, December 29, December 30, 2017 2017 2016 2014 2013 2012 GAAP earnings per share attrib
Slide 14: Footnotes to the Itemized Reconciliation Between GAAP and Non-GAAP Measures
Footnotes to the Itemized Reconciliation Between GAAP and Non-GAAP Measures: All amounts in tables are rounded to the nearest millions, except as otherwise noted. As a result, certain amounts may not recalculate using the rounded amounts provided. (a) Pro forma impact of weighted-average shares incl
Slide 15: Reconciliation Between GAAP and Non-GAAP Earnings Per Share and Net Income
Reconciliation Between GAAP and Non-GAAP Earnings Per Share and Net Income Attributable to Illumina Stockholders: Three Months Ended April 1, April 2, 2018 2017 GAAP earnings per share attributable to Illumina stockholders - diluted $ 1.41 $ 2.48 Amortization of acquired intangible assets 0.06 0.09
Slide 16: Footnotes to the Reconciliation Between GAAP and Non-GAAP Measures
Footnotes to the Reconciliation Between GAAP and Non- GAAP Measures: (a) Non-cash interest expense is calculated in accordance with the authoritative accounting guidance for convertible debt instruments that may be settled in cash. (b) Amount consists primarily of mark-to-market adjustments from our
Slide 17: Reconciliation Between GAAP and Non-GAAP Results of Operations as a Percent of Revenue
Reconciliation Between GAAP and Non-GAAP Results of Operations as a Percent of Revenue: Three Months Ended April 1, April 2, 2018 2017 GAAP gross profit $ 538 68.8 % $ 368 61.5 % Amortization of acquired intangible assets 8 1.0 % 11 1.9 % Impairment (a) — — 18 3.0 % Non-GAAP gross profit (b) $ 546 6
Slide 18: Footnotes to the Reconciliation Between GAAP and Non-GAAP Results of Operations
Footnotes to the Reconciliation Between GAAP and Non- GAAP Results of Operations: (a) Impairments for 2017 include $18 million impairment of an acquired intangible asset and $5 million in-process research and development. (b) Non-GAAP gross profit, included within non-GAAP operating profit, is a key
Slide 19: Reconciliation of Non-GAAP Financial Guidance
Reconciliation of Non-GAAP Financial Guidance Our future performance and financial results are subject to risks and uncertainties, and actual results could differ materially from the guidance set forth below. Some of the factors that could affect our financial results are stated above in this press